1-800-710-4674

Blog Post

Return to News Blog

Feature Story

 
OHC-Campaign-to-Conquer-Cancer-Dr-Waterhouse

Dr. David M. Waterhouse Joins Worldwide Campaign to Conquer Cancer

Kristin Deuber, Blogs, News Releases, 0 comments
February 3, 2017

 

Our very own Dr. David M. Waterhouse, a medical oncologist and chair of OHC’s clinical research program, has a very personal connection to cancer.

“After losing my father to cancer during my medical residency, I was fairly convinced that I wanted nothing to do with cancer care,” said Dr. Waterhouse. “But two years later, I did a rotation with a compassionate, inspired oncologist who introduced me to a very different side of cancer care. I entered my fellowship a year later.”

His passion for clinical research began over 20 years ago when Dr. Waterhouse received a Young Investigator Award from the Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO) to support his transition from a fellowship program to a faculty appointment. Since then, he’s devoted his career to advancing cancer research and improving patient access to the best possible treatments.

Dr. Waterhouse is honored to support CCF’s Campaign to Conquer Cancer – a campaign to conquer cancer worldwide by funding breakthrough research and sharing cutting-edge knowledge. Since it was launched in 2015, donors have given nearly $139 million to this important effort.

“I want to see more funding for the young investigators and the people just beginning their careers to help build the critical foundation that’s needed to cure this disease,” said Dr. Waterhouse. “That’s why I am so excited to partner with the Conquer Cancer Foundation to help them raise the important seed money to help propel the careers of bright young researchers.”

Read more about why Dr. Waterhouse has committed to supporting the next generation of cancer researchers in ASCO’s Connection Researcher Spotlight.

OHC clinical research team was instrumental in the FDA decision to approve Nivolumab as a result of their vigorous clinical trial enrollment and data outcomes for this immunotherapy drug. “Through the dedication of the OHC team and ability to share research across all health care systems, we can make a difference in the lives of cancer patients,” said Dr. Waterhouse.

To learn more about reducing your risk of cancer or OHC’s cancer treatments, please browse our website and download our patient newsletters. Or call us toll-free at 1-844-424-6673.

 
 

Leave a Reply

Your email address will not be published. Required fields are marked *